squalene synthase

Squalene synthase-IN-2 (compound isomer A-(1S, 3R)-14i) is an orally active inhibitor of squalene synthase, with IC50 values of 3.4 nM for squalene synthase and 99 nM for cholesterol synthesis enzymes. Squalene synthase-IN-2 effectively reduces plasma cholesterol and triglycerides.

Squalene synthase-IN-1 (compound 1) is a potent antihyperlipidemic agent that inhibits Squalene Synthase, demonstrating exceptional antioxidant and anti-inflammatory activities. It significantly reduces glucose and oxidative stress levels without causing toxicity [1].

RPR107393 free base is a selective and potent inhibitor of squalene synthase (SQS) for the study of neurological disorders and endocrine and metabolic disorders.

Lapaquistat acetate (TAK-475) is a squalene synthase inhibitor with potential anti-inflammatory activity. It mitigates statin-induced toxicity in human skeletal muscle cells and protects guinea pigs from simvastatin-induced myotoxicity, useful for research on hypercholesterolemia and HMG-CoA reductase deficiency.

YM-53601 is a potent squalene synthase (SQS) inhibitor that inhibits adipogenic biosynthesis and lipid secretion in rodents.YM-53601 is a cholesterol-lowering agent that inhibits farnesyl diphosphate farnesyltransferase 1 (FDFT1).YM-53601 exhibits potential antiviral activity and enhances adriamycin-mediated HCC arrest and cell death in vivo. MJN228 is a lipid-based enzyme.

SQS-IN-1 is an inhibitor of squalene synthase (SQS). It exhibits potent and broad-spectrum antiproliferative effects on various murine and human lung cancer cell lines. SQS-IN-1 impedes DNA replication and cell cycle progression, resulting in mitochondrial hyperpolarization and inducing apoptosis. Additionally, it hinders cell migration and invasion. SQS-IN-1 is applicable in lung cancer research.

RPR107393 is an orally active and selective inhibitor of squalene synthase (SQS). It inhibits squalene synthase in rat liver microsomes with an IC50 of 0.8 nM. By increasing cellular farnesol and its derivatives, RPR107393 suppresses fatty acid biosynthesis, thereby reducing triglyceride synthesis. It also lowers plasma cholesterol in rats and marmosets. RPR107393 is applicable in research related to metabolic diseases, such as hypercholesterolemia, hypertriglyceridemia, and atherosclerosis [1][2].

WC-9 is a squalene synthase inhibitor. It acts by binding to TcSQS and HsSQS.

Zaragozic acid C is an effective inhibitor of squalene synthase.

Squalestatin 2 is an inhibitor of squalene synthase.

Squalestatin 3 is an inhibitor of squalene synthase.

DF-461 is an inhibitor of squalene synthase.

Zaragozic acid D inhibits squalene synthase and ras farnesyl-protein transferase isolated from the keratinophilic fungus Amauroascus niger.

Zaragozic acid D(2) inhibits squalene synthase and ras farnesyl-protein transferase isolated from the keratinophilic fungus Amauroascus niger.

E5700 is a novel squalene synthase inhibitor with oral activity.

J-104118 potentially inhibits squalene synthase.

YM-75440 is an squalene synthase inhibitor with oral activity.

FIN56 is an iron death-specific inducer that binds to and activates squalene synthase, inducing ferroptosis by triggering GPX4 degradation. FIN56 can be used in studies of ferroptosis regulatory mechanisms, autophagy-ferroptosis crosstalk, and tumor therapy.

BMS-187745 is a squalene synthase inhibitor.

Schizostatin is an inhibitor of squalene synthase with an IC50 value of 0.84 μM.

Zaragozic acid A trisodium, a metabolite produced by fungi, serves as a reversible competitive inhibitor of squalene synthase.